Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2022

View Archived Issues

Novel ER modulator daidzein analogues confer antitumoral effect in prostate cancer

Machine learning approach speeds resistance identification

BeiGene discloses non-receptor tyrosine-protein kinase TYK2 inhibitors

New GLP-1 receptor agonists identified at Guangzhou Henovcom Bioscience

Celgene presents new cereblon-binding PROTACs

New glucocorticoid receptor antagonists discovered at Corcept Therapeutics

Viral replication inhibitors patented by Gilead

New 3,5-diaryl-substituted pyrazoles inhibit prostate cancer cell growth

Targeting IP3R-mediated Ca2+ homeostasis in adipocytes as strategy against metabolic disease

AstraZeneca and Scorpion collaborate on therapeutics against transcription factors for cancer

Intranasal influenza-based boost vaccination for preventing SARS-CoV-2 infection

Vir expands partnership with Gates Foundation in HIV and malaria

Preclinical data confirm anticancer activity of two lead compounds in Captor's CT-01 program in HCC

Novel genes identified with risk of obsessive-compulsive disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...